title: Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis?
abstract: BACKGROUND
  It is not known whether statin treatment improves clinical outcomes and reduces aortic stenosis progression in non-rheumatic calcific aortic stenosis.
  
  
  OBJECTIVE
  A meta-analysis of studies was performed comparing statin therapy with placebo or no treatment on outcomes and on aortic stenosis progression echocardiographic parameters.
  
  
  METHODS
  The authors searched Medline and Pubmed up to January 2010.
  
  
  METHODS
  Two independent reviewers independently abstracted information on study design (prospective vs retrospective or randomised vs non-randomised), study and participant characteristics. Fixed and random effects models were used. A-priori subanalyses assessed the effect of statins on low-quality (retrospective or non-randomised) and on high-quality (prospective or randomised) studies separately.
  
  
  RESULTS
  Meta-analysis identified 10 studies with a total of 3822 participants (2214 non-statin-treated and 1608 statin-treated); five studies were classified as prospective and five as retrospective; concerning randomisation, three trials were randomised whereas seven were not. No significant differences were found in all-cause mortality, cardiovascular mortality or in the need for aortic valve surgery. Lower-quality (retrospective or non-randomised) studies showed that, in statin-treated patients, the annual increase in peak aortic jet velocity and the annual decrease in aortic valve area were lower, but this was not confirmed by the analysis in high-quality (prospective or randomised) studies. Statins did not significantly affect the progression over time of peak and mean aortic gradient.
  
  
  CONCLUSIONS
  Currently available data do not support the use of statins to improve outcomes and to reduce disease progression in non-rheumatic calcific aortic valve stenosis.
authors.affiliation: Unit for Clinical Research in Atherothrombosis, Centro Cardiologico Monzino IRCCS; Department of Cardiovascular Sciences, University of Milan, Milan, Italy. alessandro.parolari@cardiologicomonzino.it
authors.forename: Alessandro
authors.initials: A
authors.lastname: Parolari
authors.forename: Elena
authors.initials: E
authors.lastname: Tremoli
authors.forename: Laura
authors.initials: L
authors.lastname: Cavallotti
authors.forename: Matteo
authors.initials: M
authors.lastname: Trezzi
authors.forename: Samer
authors.initials: S
authors.lastname: Kassem
authors.forename: Claudia
authors.initials: C
authors.lastname: Loardi
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Veglia
authors.forename: Giovanni
authors.initials: G
authors.lastname: Ferrari
authors.forename: Davide
authors.initials: D
authors.lastname: Pacini
authors.forename: Francesco
authors.initials: F
authors.lastname: Alamanni
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001024:Aortic Valve Stenosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D002114:Calcinosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D018450:Disease Progression; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008875:Middle Aged; D012214:Rheumatic Heart Disease; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors